Save Product
Product Details
Materials Provided
IDComponentsSizeEP138-C01High-bind Plate1 plateEP138-C02Human SIRP alpha15 μgEP138-C03Biotinylated Human CD4710 μgEP138-C04Anti-CD47 Neutralizing Antibody20 μgEP138-C05Streptavidin-HRP10 μgEP138-C06Coating Buffer12 mLEP138-C0710xWashing Buffer50 mLEP138-C08Blocking Buffer50 mLEP138-C09Substrate Solution12 mLEP138-C10Stop Solution7 mLProduct Overview
CD47 [Biotinylated] : SIRP alpha Inhibitor Screening ELISA Kit is based on a competition-ELISA method, is used to screening for inhibitors of human CD47 binding to human SIRP alpha. The kit is designed to provide a reliable solution for the screening of antibodies and small molecule inhibitors in the early stages, as well as QC release, to help researchers quickly screen and validate drugs, effectively improving research and development efficiency. It can also be used as a universal detection tool to identify the ability of human CD47 binding to human SIRP alpha.
Reconstitution
Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
Storage
1. Unopened kit should be stored at 2℃-8℃ upon receiving.
2. Find the expiration date on the outside packaging and do not use reagents past their expiration date.
3. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Typical Data
Please refer to DS document for the assay protocol.
INHIBITION OF CD47[Biotinylated]: SIRP alpha BINDING BY ANTI-CD47 NEUTRALIZING AN-TIBODY
Serial dilutions of Anti-CD47 Neutralizing antibody (Catalog # EP138-C04) (1:1 serial dilution, from 10 μg/mL to 0.01μg/mL) was added into Biotinylated CD47: SIRP alpha binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).
Customer Reviews Writing Reviews
Recent Advances
Drug Development Progress- English Name：
Cluster of differentiation 47
- Category：
- Approved Drugs：
0 Details
- Drugs in Clinical Trials：
53 Details
- Highest Development Stage：
Phase 3 Clinical
Contact Us
Drug Candidate Licensing
